This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented)

A compound of formula I

$$(R^{1})_{p} \xrightarrow{\qquad \qquad N \qquad } (CHR^{2})_{n} \xrightarrow{\qquad \qquad } N$$

wherein

R1 is H, OH, OA, CN, Hal, COR or CH2R,

R is by OH, OA, NH₂, NHA or NA₂,

R² and R³ are H or A,

A is an alkyl group with 1-10 atoms,

X is O or S,

Hal is F, Cl, Br or I

n is 2-6,

m is 1-4

p is 0, 1, 2, 3 or 4

or a salt, enantiomer, solvate, racemate or mixture of enantiomers thereof.

2. (Previously Presented) or CN.

A compound according to claim 1, wherein R1 is F

3. (Previously Presented)

A compound according to claim 1, wherein R³ is H.

- 4. (Canceled)
- 5. (Canceled)
- 6. (Currently Amended) to I5:

A compound according to claim 1 of the formula I1

and their salts, solvates, enantiomeres and racemates or a salt, solvate, enantiomer or racemate thereof.

- 7. (Previously Presented) A pharmaceutical composition comprising a formula I according to Claim 1 or physiologically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.
- 8. (Canceled)
- 9. (Previously Presented) A method of inhibiting serotonin reuptake, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.
- 10. (**Previously Presented**) A method of achieving a 5HT1A antagonistic effect, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.
- 11. (Canceled)
- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)

15. (Currently Amended) A method for the treatment of illnesses of the central nervous system, in particular of mental disorders of the schizophrenia, or for the control of psychotic anxiety states, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.